Study of GB-4362 with EV and pembrolizumab for bladder cancer
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new study drug (GB-4362) when added to the usual combination of enfortumab vedotin and pembrolizumab for advanced bladder cancer. It is for people who are about to start this standard treatment and have not had these drugs before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are scheduled to start standard treatment with enfortumab vedotin (EV) and pembrolizumab for advanced bladder cancer.
- You have not had EV or a similar drug before.
- You are generally healthy enough to be up and about (ECOG score 0 or 1).
- You weigh at least 50 kg (about 110 lbs).
- You do not have uncontrolled diabetes or active cancer in your brain that has not been treated.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, CA-4948, combined with pembrolizumab (Keytruda) for people with advanced bladder cancer that grew after prior immunotherapy. The goal is to see if this combination can help when standard treatments stop working.
This trial tests a two-drug combination (pembrolizumab and enfortumab vedotin) followed by maintenance pembrolizumab for people with advanced bladder cancer that has not been treated before. The goal is to see if this approach helps control the cancer for longer.
This trial tests a new drug combination (pembrolizumab and sacituzumab govitecan) against standard treatment for advanced bladder cancer that has spread or cannot be removed by surgery. It's for people who have already tried an immunotherapy drug like pembrolizumab and another drug called enfortumab vedotin.
This Phase 1 study tests whether cabozantinib combined with enfortumab vedotin can help people with advanced urothelial (bladder) cancer that has already been treated with immunotherapy (PD-1/PD-L1) and usually chemotherapy. It aims to find a safer dose and see if the combo can shrink tumors or control the disease.
This trial tests whether two drugs (enfortumab vedotin and pembrolizumab) work better than radiation with chemotherapy for muscle-invasive bladder cancer. The goal is to treat your cancer while keeping your bladder instead of removing it.
This study tests a new drug (LY4052031) for people with several types of advanced solid tumors, especially bladder cancer. It aims to see if the drug is safe and effective when given alone or after other treatments have stopped working.
Hear when a new Advanced Urothelial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.